Free Trial

Analysts Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Target Price at $15.60

Y-mAbs Therapeutics logo with Medical background

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eleven analysts that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, seven have given a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $15.60.

Several brokerages recently weighed in on YMAB. Truist Financial lowered their price objective on Y-mAbs Therapeutics from $18.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Bank of America lowered Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price objective for the company. in a report on Tuesday, April 22nd. HC Wainwright lowered their price objective on Y-mAbs Therapeutics from $12.00 to $11.00 and set a "buy" rating for the company in a report on Monday, May 19th. Oppenheimer lowered their price objective on Y-mAbs Therapeutics from $20.00 to $15.00 and set an "outperform" rating for the company in a report on Thursday, May 29th. Finally, Wedbush reissued an "outperform" rating and issued a $18.00 price objective (down from $21.00) on shares of Y-mAbs Therapeutics in a report on Wednesday, May 28th.

View Our Latest Report on YMAB

Institutional Investors Weigh In On Y-mAbs Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of YMAB. Acorn Capital Advisors LLC acquired a new stake in shares of Y-mAbs Therapeutics during the 4th quarter valued at $22,408,000. Caligan Partners LP raised its stake in Y-mAbs Therapeutics by 47.9% during the 4th quarter. Caligan Partners LP now owns 1,767,982 shares of the company's stock valued at $13,843,000 after purchasing an additional 572,729 shares during the period. Infinitum Asset Management LLC acquired a new stake in Y-mAbs Therapeutics during the 4th quarter valued at $1,218,000. Paradigm Biocapital Advisors LP raised its stake in Y-mAbs Therapeutics by 3.7% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,236,346 shares of the company's stock valued at $33,171,000 after purchasing an additional 150,000 shares during the period. Finally, AQR Capital Management LLC raised its stake in Y-mAbs Therapeutics by 869.3% during the 1st quarter. AQR Capital Management LLC now owns 164,788 shares of the company's stock valued at $730,000 after purchasing an additional 147,788 shares during the period. Institutional investors and hedge funds own 70.85% of the company's stock.

Y-mAbs Therapeutics Trading Down 1.9%

Shares of YMAB traded down $0.08 during midday trading on Friday, reaching $4.22. 168,824 shares of the company were exchanged, compared to its average volume of 297,944. The stock has a 50-day moving average price of $4.47 and a 200-day moving average price of $5.28. The company has a market cap of $191.08 million, a price-to-earnings ratio of -6.59 and a beta of 0.51. Y-mAbs Therapeutics has a 1-year low of $3.55 and a 1-year high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.10. Y-mAbs Therapeutics had a negative return on equity of 30.59% and a negative net margin of 31.84%. The business had revenue of $20.90 million for the quarter, compared to analyst estimates of $19.97 million. Equities research analysts anticipate that Y-mAbs Therapeutics will post -0.65 earnings per share for the current year.

About Y-mAbs Therapeutics

(Get Free Report

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

Read More

Analyst Recommendations for Y-mAbs Therapeutics (NASDAQ:YMAB)

Should You Invest $1,000 in Y-mAbs Therapeutics Right Now?

Before you consider Y-mAbs Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Y-mAbs Therapeutics wasn't on the list.

While Y-mAbs Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines